Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Cash runway to fund pipeline development and operations into the first half of 2028

EPRX

<p>在接受 EP-104GI 单次治疗后，观察到持续的症状和组织反应，持续时间达到 52 周。RESOLVE 试验的第 2b 阶段仍在招募中，预计将在 2026 年第三季度公布初步数据。现金流将支持管线开发和运营，持续到 2028 年上半年</p>

Eupraxia Pharmaceuticals 公布 2025 年第三季度财务结果